Zongli Zheng

Dr Zheng received his PhD degree from Karolinska Institutet in 2011. Based on large-scale longtudinal cohort, his doctoral study focused on identification of molecular determinants in Helicobacter pylori and its host for the development of stomach cancer. He also developed a novel titration-free library preparation method for next generation sequencing. He then moved to United States for postdoc training, where he focused on clincial sequencing for cancer patients for targeted therapy and the CRISPR genome editing tools to characterize and refine its off-targets.

With a focus in technology advancement here at MWLC, we are interested in developing novel technologies integrating next-generation sequencing, single cell and genome editing platforms. Resolution, scalability, flexibility and precision of these technologies remain to be drastically improved in order to answer many fundamental and long-standing biological questions. We aim to develop new technology for genomic characterization and functional screening to identify biomarkers for predicting cell state, and disease treatment and progression.

Dr Zongli Zheng together with his team members.

Group members

Maggie Chow Research Officer
Athena Chu Senior Research Assistant
Jan Keung Research Officer
Qinle Zhang Postdoc
Zongli Zheng Assistant Professor

We are looking for highly motivated individuals with background in molecular biology, NGS, Biostatistics, Bioinformatics and software engineering to join our group at the research assistant and postdoctoral levels. Interested candidates please contact Dr Zheng at Zongli.Zheng@ki.se.

Selected publications

Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP.  Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine. 2014 Dec;20(12):1479-84

Tsai SQ*, Zheng Z*, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, Aryee MJ, Joung KJ. Genome-wide off-target mutation profiles of CRISPR-Cas nucleases in human cells. Nature Biotechnology. 2015 Feb;33(2):187-197  (*Contributed equally)

Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016 Jan 28;529(7587):490-5 

CentreRegenerative MedicineStem Cell Biology